There are many challenges in oxalosis, including prompt, clinical recognition of this inborn error of metabolism, management of its many medical problems, provision of adequate care at end-stage kidney disease, and optimizing both the timing and results of liver and kidney allografts. This review provides a framework for the interested clinician to understand the many problems, and to begin to assimilate knowledge about an increasingly recognized, metabolic disorder. It ends with potential, innovative therapies that are not yet at the patient's bedside.
Copyright 2001 by the National Kidney Foundation, Inc.